Luk H. Vandenberghe, Ph.D.
- AMD Center of Excellence
- Cornea Center of Excellence
- Mobility Enhancement and Vision Rehabilitation Center of Excellence
- Ocular Genomics Institute
- Ocular Regenerative Medicine Institute
Through the study and development of technologies that overcome current translational hurdles, Dr. Vandenberghe is helping to position gene therapy as a broadly applicable clinical modality in ophthalmology. Previously, he developed a novel adena-associated viral vector (AAV) platform, and in translational studies, he characterized those for safety and efficacy parameters in large animal models. His current research focus is on gene therapy for neurosensory disorders, especially retinal blindness. He is on the editorial board of Molecular Therapy and an active member of the American Society of Cell and Gene Therapy, for which he chairs the educational committee. In addition, he co-founded GenSight Biologics, a biotech entity that pursues innovative ocular gene therapy strategies.